NASDAQ · SLN
Healthcare · Biotechnology
$19.76
Up+$0.02 (+0.10%)
Updated Nov 3, 2026, 10:01 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
SLN closed at $19.76 after 21 trading sessions, up 94.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $19.75 | $19.80 | $19.75 | $19.76 | 1.19M |
| Oct 30, 2026 | $19.74 | $19.80 | $19.74 | $19.75 | 621.43K |
| Oct 29, 2026 | $19.71 | $19.80 | $19.71 | $19.80 | 1.81M |
| Oct 28, 2026 | $19.76 | $19.79 | $19.70 | $19.71 | 2.76M |
| Oct 27, 2026 | $19.75 | $19.80 | $19.7101 | $19.78 | 1.49M |
| Oct 26, 2026 | $19.66 | $19.865 | $19.65 | $19.78 | 4.65M |
| Oct 23, 2026 | $19.65 | $19.68 | $19.65 | $19.67 | 2.13M |
| Oct 22, 2026 | $19.69 | $19.69 | $19.625 | $19.66 | 3.08M |
| Oct 21, 2026 | $19.61 | $19.67 | $19.60 | $19.67 | 2.8M |
| Oct 20, 2026 | $19.58 | $19.65 | $19.57 | $19.61 | 13.96M |
| Oct 19, 2026 | $19.585 | $19.61 | $19.56 | $19.58 | 71.92M |
| Oct 16, 2026 | $9.10 | $9.22 | $8.66 | $8.68 | 1.13M |
| Oct 15, 2026 | $8.81 | $9.46 | $8.81 | $9.35 | 2.57M |
| Oct 14, 2026 | $8.91 | $9.27 | $8.85 | $8.98 | 1.23M |
| Oct 13, 2026 | $9.53 | $9.565 | $8.71 | $8.87 | 1.45M |
| Oct 12, 2026 | $9.70 | $10.355 | $9.58 | $9.65 | 550.99K |
| Oct 9, 2026 | $9.45 | $10.39 | $9.45 | $9.86 | 844.35K |
| Oct 8, 2026 | $9.71 | $9.72 | $9.055 | $9.52 | 1.11M |
| Oct 7, 2026 | $9.77 | $10.14 | $9.60 | $9.82 | 1.32M |
| Oct 6, 2026 | $10.12 | $10.185 | $9.63 | $9.83 | 1.58M |
| Oct 5, 2026 | $10.62 | $10.65 | $10.0527 | $10.14 | 976.3K |
The latest Smart Investors Daily articles mentioning SLN.
Company
Market Activity
Research & News
SLN research
Company profile and research snapshot.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 21, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio downgrades Silence Therapeutics (NASDAQ:SLN) from Buy to Neutral and lowers the price target from $75 to $20.
Yahoo · Oct 20, 2026
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Benzinga · Oct 20, 2026
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Yahoo · Oct 20, 2026
Silence Therapeutics has surged into the spotlight after a sharp re-rating of its share price and a takeover agreement, which puts fresh focus on a simple question for investors. With the stock now trading near the agreed acquisition level, the open issue is how well that price lines up against the company’s book value. With a year to date gain of about 218%, the stock’s rapid rerating puts more weight on whether the current level can be grounded in the balance sheet rather than short term...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLN.
